Engineering of stealth (maghemite/PLGA)/chitosan (core/shell)/shell nanocomposites with potential applications for combined MRI and hyperthermia against cancer

Fernández-Álvarez, Fátima; Caro, Carlos; García-García, Gracia; García-Martín, María Luisa; Arias, José L.

doi:10.1039/d1tb00354b

Cited by 18 publications

(11 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While under pH ≈ 7.4, MTX shows a sustained release over the next 90 h, the chemotherapeutic is completely released within 3 h under acidic conditions (pH 5.5). The observed pH-responsiveness, as previously documented in studies involving CS-coated NPs [38,40], may be attributed to the presence of the hydrophilic CS coating. With a pKa of 6.5, the amine groups of CS undergo ionization in acidic solutions, making it more soluble at lower pH levels.…”

Section: Discussionsupporting

confidence: 73%

See 1 more Smart Citation

Magnetic and pH-Responsive Magnetite/Chitosan (Core/Shell) Nanoparticles for Dual-Targeted Methotrexate Delivery in Cancer Therapy

Medina-Moreno,

El-Hammadi,

Martínez-Soler

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Methotrexate successful therapy encounters various challenges in chemotherapy, such as poor oral bioavailability, low specificity, side effects and the development of drug resistances. In this study, we propose a dual-targeted nanocarrier comprising magnetite/chitosan nanoparticles for an efficient Methotrexate delivery. The synthesis of the particles was confirmed through morphological analysis using electron microscopy and elemental mappings via energy dispersive X-ray spectroscopy. These nanoparticles exhibited a size of ≈ 270 nm, a zeta potential of ≈ 24 mV, and magnetic responsiveness, as demonstrated by hysteresis cycle analysis and visual observations under a magnetic field. In addition, these core/shell particles displayed high stability, as evidenced by size and surface electric charge measurements, during storage at both 4 ºC and 25 ºC for at least 30 days. Electrophoretic properties were examined in relation to pH and ionic strength, confirming the stability. The nanoparticles demonstrated a pH-responsive drug release as observed by a sustained Methotrexate release over the next 90 h under pH ≈ 7.4, while complete release occurred within 3 h under acidic conditions (pH ≈ 5.5). In the ex vivo biocompatibility assessment, the magnetite/chitosan particles showed excellent hemocompatibility and no cytotoxic effects on normal MCF-10A and cancer MCF-7 cells. Furthermore, the Methotrexate-loaded nanoparticles significantly enhanced the antitumor activity reducing the half-maximal inhibitory concentration by ≈ 2.7-fold less compared to the free chemotherapeutic.

show abstract

Section: Discussionsupporting

confidence: 73%

“…An assessment of the CS coating on Fe 3 O 4 NPs was conducted by analyzing the in uence of pH and ionic strength on the ζ of the particles [39,40,58]. To assess the effect of pH, the study encompassed a range from pH 3 to 9, in the presence of 1 mM NaCl.…”

Section: Characterization Of Size Surface Electrical Charge and Short...mentioning

confidence: 99%

Magnetic and pH-Responsive Magnetite/Chitosan (Core/Shell) Nanoparticles for Dual-Targeted Methotrexate Delivery in Cancer Therapy

Medina-Moreno,

El-Hammadi,

Martínez-Soler

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…A combination of OXA with magnetic hyperthermia, through superparamagnetic iron oxide nanoparticles (IO), could improve diagnosis and cancer therapy, as magnetic hyperthermia enables one to target the heating source at the tumor tissues, through the application of an external magnetic field [63]. Promising results have been reported using multifunctional platforms for colorectal cancer therapy [64,65]. In a study by Lima et al, the platform was designed based on polyethylene glycol-polylactic acid (PEG-PLA) nanospheres to co-deliver methotrexate and IO nanoparticles, proving increased cytotoxicity towards Caco-2 and SW-480 colon cancer cells [66].…”

Section: Discussionmentioning

confidence: 99%

Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma

Zumaya

Rimpelová

Štějdířová

et al. 2022

IJMS

View full text Add to dashboard Cite

Anti-CD133 monoclonal antibody (Ab)-conjugated poly(lactide-co-glycolide) (PLGA) nanocarriers, for the targeted delivery of oxaliplatin (OXA) and superparamagnetic nanoparticles (IO-OA) to colorectal cancer cells (CaCo-2), were designed, synthesized, characterized, and evaluated in this study. The co-encapsulation of OXA and IO-OA was achieved in two types of polymeric carriers, namely, PLGA and poly(lactide-co-glycolide)-poly(ethylene glycol) (PLGA-PEG) by double emulsion. PLGA_IO-OA_OXA and PEGylated PLGA_IO-OA_OXA nanoparticles displayed a comparable mean diameter of 207 ± 70 nm and 185 ± 119 nm, respectively. The concentration of the released OXA from the PEGylated PLGA_IO-OA_OXA increased very rapidly, reaching ~100% release after only 2 h, while the PLGA_IO-OA_OXA displayed a slower and sustained drug release. Therefore, for a controlled OXA release, non-PEGylated PLGA nanoparticles were more convenient. Interestingly, preservation of the superparamagnetic behavior of the IO-OA, without magnetic hysteresis all along the dissolution process, was observed. The non-PEGylated nanoparticles (PLGA_OXA, PLGA_IO-OA_OXA) were selected for the anti-CD133 Ab conjugation. The affinity of Ab-coated nanoparticles for CD133-positive cells was examined using fluorescence microscopy in CaCo-2 cells, which was followed by a viability assay.

show abstract

“…It is biocompatible and biodegradable, and its –NH 2 groups can be protonated at low pH, imparting a positive charge and, thus, mucosal adhesive properties to the macromolecule [ 97 ]. Therefore, CS-coated PLGA nanosystems can increase biocompatibility, protect from opsonization and improve retention and cellular uptake [ 98 , 99 ]. Additionally, CS coating has been used as a strategy to achieve sustained and pH-responsive drug release from PLGA nanostructures [ 100 , 101 , 102 ].…”

Section: Surface Modification Strategiesmentioning

confidence: 99%

Recent Advances in the Surface Functionalization of PLGA-Based Nanomedicines

El-Hammadi

Arias

2022

Nanomaterials

Self Cite

View full text Add to dashboard Cite

Therapeutics are habitually characterized by short plasma half-lives and little affinity for targeted cells. To overcome these challenges, nanoparticulate systems have entered into the disease arena. Poly(d,l-lactide-co-glycolide) (PLGA) is one of the most relevant biocompatible materials to construct drug nanocarriers. Understanding the physical chemistry of this copolymer and current knowledge of its biological fate will help in engineering efficient PLGA-based nanomedicines. Surface modification of the nanoparticle structure has been proposed as a required functionalization to optimize the performance in biological systems and to localize the PLGA colloid into the site of action. In this review, a background is provided on the properties and biodegradation of the copolymer. Methods to formulate PLGA nanoparticles, as well as their in vitro performance and in vivo fate, are briefly discussed. In addition, a special focus is placed on the analysis of current research in the use of surface modification strategies to engineer PLGA nanoparticles, i.e., PEGylation and the use of PEG alternatives, surfactants and lipids to improve in vitro and in vivo stability and to create hydrophilic shells or stealth protection for the nanoparticle. Finally, an update on the use of ligands to decorate the surface of PLGA nanomedicines is included in the review.

show abstract

Engineering of stealth (maghemite/PLGA)/chitosan (core/shell)/shell nanocomposites with potential applications for combined MRI and hyperthermia against cancer

Cited by 18 publications

References 114 publications

Magnetic and pH-Responsive Magnetite/Chitosan (Core/Shell) Nanoparticles for Dual-Targeted Methotrexate Delivery in Cancer Therapy

Magnetic and pH-Responsive Magnetite/Chitosan (Core/Shell) Nanoparticles for Dual-Targeted Methotrexate Delivery in Cancer Therapy

Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma

Recent Advances in the Surface Functionalization of PLGA-Based Nanomedicines

Contact Info

Product

Resources

About